Mental Health Clinics in East Windsor, CT Accepting Medicare
6 Mental Health Clinics found. Showing 1 - 6
 Inner Peace Psychotherapy, Llc Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 9a Pasco Dr, East Windsor, CT 06088 Phone: 860-977-6272 |
Effective Solutions Counseling, Llc Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 9a Pasco Dr, East Windsor, CT 06088 Phone: 860-331-4251 |
Karuna Psychological Services, Llc Psychologist - Adult Development & Aging Medicare: Medicare Enrolled Practice Location: 7c Pasco Dr, East Windsor, CT 06088 Phone: 860-623-1777 |
Pathways To Empowerment, Llc Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 99 Main St, Suite 1, East Windsor, CT 06088 Phone: 860-670-4997 |
Eastern Services & Camp Simon, Llc Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 115 Bridge St, Suite C, East Windsor, CT 06088 Phone: 860-254-5127 Fax: 860-254-5254 |
Hope In Healing Therapy Incorporated Counselor Medicare: Not Enrolled in Medicare Practice Location: 261 Scantic Rd, East Windsor, CT 06088 Phone: 860-265-4146 |
News Archive
Anxiety may contribute to cognitive dysfunction in bipolar disorder
Compromised cognitive and adaptive functioning in euthymic patients with bipolar disorder may be partly explained by related comorbid anxiety, suggest researchers.
Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD
Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company's Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson's Disease (PD).
Study provides information that validates genetic basis of adaptation to high altitudes
Research led by scientists from the University of California, San Diego has decoded the genetic basis of chronic mountain sickness (CMS) or Monge's disease. Their study provides important information that validates the genetic basis of adaptation to high altitudes, and provides potential targets for CMS treatment.
FDA approval of Tysabri, for the treatment of multiple sclerosis
Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.
› Verified 8 days ago